t(X;14)(p11;q32) in MALT lymphoma involving GPR34 reveals a role for GPR34 in tumor cell growth.
Blood., Nov;120(19):3949-57 (2012)
Molecular pathogenesis of Waldenstrom's macroglobulinemia.
Haematologica., Sep;97(9):1281-90 (2012)
Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.
J Pain Symptom Manage., Jun;43(6):1094-104 (2012)
Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides.
Blood., Aug;120(5):1060-6 (2012)
Thrombosis in multiple myeloma (MM).
Hematology., Apr;17 Suppl 1:S177-80 (2012)
Frontline treatment of multiple myeloma.
Hematology., Apr;17 Suppl 1:S101-4 (2012)
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial.
Blood., May;119(21):4860-7 (2012)
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis.
Blood., Jun;119(23):5397-404 (2012)
Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.
Blood., May;119(19):4391-4 (2012)
Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogenetics.
Blood., Mar;119(9):2100-5 (2012)
A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma.
Br. J. Haematol., Feb;156(3):326-33 (2012)
A pilot program in collaboration with African American churches successfully increases awareness of the importance of cancer research and participation in cancer translational research studies among African Americans.
J Cancer Educ., Jun;27(2):294-8 (2012)
Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Blood., Nov;118(18):4771-9 (2011)
Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.
Blood., Oct;118(16):4359-62 (2011)
Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants.
Transplantation., Sep;92(5):570-4 (2011)
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.
Am. J. Hematol., Aug;86(8):640-5 (2011)
Establishment and characterization of a novel Waldenstrom macroglobulinemia cell line, MWCL-1.
Blood., May;117(19):e190-7 (2011)
Plasma cell leukemia.
Blood Rev., May;25(3):107-12 (2011)
Diagnosis and management of WaldenstrÃ¶m macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Mayo Clin. Proc., Sep;85(9):824-33 (2010)
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma.
Am. J. Hematol., Sep;85(9):664-9 (2010)